Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL	B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, high grade B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, primary mediastinal large B-cell lymphoma	Active, not recruiting	Phase 2	2025-02-11		NCT06093841

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Shanghai Ming Ju Biotechnology Co., Ltd.	7

13 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Tongren Hospital	Beijing	China	10
Henan Cancer Hospital	Zhengzhou	China	98
Hunan Cancer Hospital	Changsha	China	87
Institute of Hematology&Hospital of Blood Disease CAMS	Tianjin	China	1
Jiangsu Provincial People's Hospital	Nanjing	China	8
Peking Union Medical College Hospital	Beijing	China	112
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,	Shanghai	China	1
Shandong Cancer Hospital	Jinan	China	31
Sun Yat-Sen University Cancer Hospital	Guangzhou	China	6
The First Affiliated Hospital of Soochow University	Suzhou	China	101
The First Affiliated Hospital of Zhejiang University School of Medicine	Hangzhou	China	18
The First Affiliated Hospital of Zhengzhou University	Zhengzhou	China	103
Tianjin Cancer Hospital	Tianjin	China	14